Skip to content

Improving the Diagnostic of Tuberculosis

Improving the Diagnostic of Tuberculosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02861768
Enrollment
991
Registered
2016-08-10
Start date
2013-03-22
Completion date
2019-02-08
Last updated
2023-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Brief summary

The presence of M. tuberculosis in non-invasive throat swabs of patients withdrawn for suspected tuberculosis. Hypothesis 10% of patients infected by M. tuberculosis are carrier of M. tuberculosis pharyngeal. Secondary 1. Measure the time to diagnosis of pulmonary TB by comparing the sample versus noninvasive pharyngeal samples taken routinely. 2. Evaluation of the direct cost of the diagnosis of M. tuberculosis by comparing the sample versus noninvasive pharyngeal samples taken routinely. 3. Beijing genotype prevalence among patients with pulmonary tuberculosis.

Interventions

BIOLOGICALPharyngeal swab

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient taken for microbiological examinations kit mycobacterium * Patient Major (\> 18 years). * Patient who freely signed the informed written consent. * Patient affiliated to a system of social security.

Exclusion criteria

* Patient minor (\<18 years). * Patient pregnant or nursing. * Major Patient under guardianship. * Private Patient liberty or under court order. * Patient refusing to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Percentage of patients with microbiological diagnosis of M. tuberculosis infection3 years

Secondary

MeasureTime frameDescription
pulmonary tuberculosis diagnostic time.3years
Prevalence of diagnosed patients Beijing3 years
Direct cost of microbiological diagnosis of extra Beijing genotype3 years(compared to the cost of the kit TB), reported the percentage of patients diagnosed Beijing.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026